Absence of inclusion body formation in the MPTP mouse model of Parkinson's disease.

[1]  D. Perl,et al.  Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease , 2004, Annals of neurology.

[2]  W. Dauer,et al.  Parkinson's Disease Mechanisms and Models , 2003, Neuron.

[3]  B. Giasson,et al.  Effects of Oxidative and Nitrative Challenges on α-Synuclein Fibrillogenesis Involve Distinct Mechanisms of Protein Modifications* , 2003, Journal of Biological Chemistry.

[4]  S. Totterdell,et al.  Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson’s disease , 2002, Brain Research.

[5]  Robert Burke,et al.  Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Ted M. Dawson,et al.  Animal Models of PD Pieces of the Same Puzzle? , 2002, Neuron.

[7]  S. Totterdell,et al.  Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment , 2001, Neuroscience.

[8]  Todd B. Sherer,et al.  Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.

[9]  J. Trojanowski,et al.  Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.

[10]  G. Irvine,et al.  Review: formation and properties of amyloid-like fibrils derived from alpha-synuclein and related proteins. , 2000, Journal of structural biology.

[11]  C A Ross,et al.  Synphilin‐1 is present in Lewy bodies in Parkinson's disease , 2000, Annals of neurology.

[12]  L. Mucke,et al.  Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. , 2000, Science.

[13]  M. Vila,et al.  α‐Synuclein Up‐Regulation in Substantia Nigra Dopaminergic Neurons Following Administration of the Parkinsonian Toxin MPTP , 2000, Journal of neurochemistry.

[14]  P. Lansbury,et al.  Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[15]  M. Beal,et al.  NOS knockouts and neuroprotection , 1999, Nature Medicine.

[16]  Ted M. Dawson,et al.  Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease , 1999, Nature Medicine.

[17]  Anders Björklund,et al.  Prospects for new restorative and neuroprotective treatments in Parkinson's disease , 1999, Nature.

[18]  D. Guastella,et al.  Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[19]  G. Bignami.  From entropy to Duino , 1999, Nature.

[20]  P. Worley,et al.  Synphilin-1 associates with α-synuclein and promotes the formation of cytosolic inclusions , 1999, Nature Genetics.

[21]  H. Braak,et al.  Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by α-synuclein immunocytochemistry , 1999, Neuroscience Letters.

[22]  J C Rothwell,et al.  Physiology and Anatomy of Possible Oscillators in the Central Nervous System , 2008, Movement disorders : official journal of the Movement Disorder Society.

[23]  Hitoshi Takahashi,et al.  Accumulation of α-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy , 1998, Acta Neuropathologica.

[24]  Takeshi Iwatsubo,et al.  Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia , 1998, Cell Death and Differentiation.

[25]  P. Jenner,et al.  Understanding cell death in parkinson's disease , 1998, Annals of neurology.

[26]  David F. Clayton,et al.  The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease , 1998, Trends in Neurosciences.

[27]  J Q Trojanowski,et al.  Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. , 1998, The American journal of pathology.

[28]  J. Langston,et al.  The etiology of Parkinson's disease with emphasis on the MPTP story , 1996, Neurology.

[29]  T. Dawson,et al.  Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Schapira Ah.  Neurotoxicity and the mechanisms of cell death in Parkinson's disease , 1996 .

[31]  C. Marsden,et al.  Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease , 1994, Annals of neurology.

[32]  D. Dickson,et al.  Pathology and Biology of the Lewy Body , 1993, Journal of neuropathology and experimental neurology.

[33]  N. Hattori,et al.  Mitochondrial energy crisis in Parkinson's disease. , 1993, Advances in neurology.

[34]  J. Langston,et al.  Similarities and differences between MPTP-induced parkinsonsim and Parkinson's disease. Neuropathologic considerations. , 1993, Advances in neurology.

[35]  J. Crampton,et al.  Effects of probenecid on striatal dopamine depletion in acute and long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice. , 1990, General pharmacology.

[36]  S. Markey,et al.  MPTP Toxicity: Implications for Research in Parkinson's Disease , 1988 .

[37]  B. A. Brooks,et al.  Variability and functional recovery in the N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of parkinsonism in monkeys , 1986, Neuroscience.

[38]  J. Langston,et al.  Permanent human parkinsonism due to 1‐methy 1–4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) , 1985, Neurology.

[39]  H. Pakkenberg,et al.  The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1985, The New England journal of medicine.

[40]  R. Duvoisin,et al.  Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors , 1984, Nature.

[41]  R. S. Burns,et al.  Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism , 1984, Nature.

[42]  D. Jacobowitz,et al.  A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[43]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.